LAUSR

PURPOSE To report on the safety, technical results and oncological outcomes of computed tomography guided percutaneous microwave ablation of stage T1b renal cell carcinoma. MATERIALS AND METHODS This single-center retrospective study investigated consecutive patients with cT1b renal cell carcinoma who were treated with computed tomographyguided percutaneous microwave ablation between December 2015 and May 2019. Patient baseline characteristics, tumor biological features, technical parameters, clinical outcomes, and complications were recorded and evaluated. Local tumor progression-free survival and overall survival rates were estimated using the Kaplan-Meier methods. RESULTS This study included 23 patients (18 men [mean age ± standard deviation, 74.6 years ± 10.2; range, 58-89 years] and 5 women [mean age, 71.6 years ±10.1; range, 62-86 years]; overall mean age, 74.0 years ± 10.0; range, 58-89 years) with 23 cT1b renal cell carcinomas. Primary technical success was achieved in 19/23 (82.6%) patients. Secondary technical success was achieved in 4/4 (100%) patients. Local tumor progression-free survival was 100.0%, 90.9%, and 90.9% at 1-, 2-, and 3-years, respectively. Overall survival was 95.2%, 85.7%, and 71.4% at 1-, 2-, and 3-years, respectively. There were 2 (8.7%) complications, both were classified as minor complications according to the Society of Interventional Radiology grading system for complication. CONCLUSIONS Computed tomography guided percutaneous microwave ablation for cT1b renal cell carcinoma is associated with high rates of technical success, excellent local tumor progression-free survival and overall survival, and low complication rates.